Enhanced kidney graft survival with retroplacental source γ-globulin: Results of a 5year prospective study at a single center

Robert R. Riggio, Manikkam Suthanthiran, Jhoong S. Cheigh, Rudy H. Haschemeyer, Marilena A. Fotino, William T. Stubenbord, Kurt H. Stenzel, Albert L. Rubin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We examined the possibility that retroplacental source γ-globulin (RPGG), with its content of anti-HLA antibodies, would improve cadaver kidney graft survival rates. In a 5-year controlled prospective study of 208 transplants, we found that the addition of RPGG to a standard immunosuppressive drug regimen (azathioprine and prednisone) resulted in significant improvement of the cumulative survival rate (CSR) of first and second grafts. At 2 years, the overall CSR of first grafts increased from a control value of 37% ± 6 to 52% ± 6 (P = 0.037). Among second graft recipients, the CSR increased from a value of 19% ± 8 to 50% ± 10 (P = 0.014). This improvement in graft survival was seen as early as 3 months after surgery and was sustained through 3 years without added recipient morbidity or mortality. When recipient populations were stratified for various factors, those groupings remonstrative of an intact or active humoral immune response capacity were found to have the highest survival rates in the study; 2-year graft CSRs of 70% ± 6 and 65% ± 10 were found in recipients with preformed antibody resulting from blood transfusions (P = 0.003) and cytomegalovirus infectivity (P = 0.0006), respectively. These findings indicate that the improved graft survival seen in this study may have resulted from a recipient’s immunological response to challenge with RPGG.

Original languageEnglish
Pages (from-to)636-641
Number of pages6
JournalTransplantation
Volume33
Issue number6
DOIs
Publication statusPublished - 1 Jan 1982
Externally publishedYes

Fingerprint

Globulins
Graft Survival
Survival Rate
Prospective Studies
Transplants
Kidney
Active Immunity
Azathioprine
Immunosuppressive Agents
Humoral Immunity
Prednisone
Cytomegalovirus
Cadaver
Blood Transfusion
Anti-Idiotypic Antibodies
Morbidity
Mortality
Antibodies
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Transplantation

Cite this

Enhanced kidney graft survival with retroplacental source γ-globulin : Results of a 5year prospective study at a single center. / Riggio, Robert R.; Suthanthiran, Manikkam; Cheigh, Jhoong S.; Haschemeyer, Rudy H.; Fotino, Marilena A.; Stubenbord, William T.; Stenzel, Kurt H.; Rubin, Albert L.

In: Transplantation, Vol. 33, No. 6, 01.01.1982, p. 636-641.

Research output: Contribution to journalArticle

Riggio, Robert R. ; Suthanthiran, Manikkam ; Cheigh, Jhoong S. ; Haschemeyer, Rudy H. ; Fotino, Marilena A. ; Stubenbord, William T. ; Stenzel, Kurt H. ; Rubin, Albert L. / Enhanced kidney graft survival with retroplacental source γ-globulin : Results of a 5year prospective study at a single center. In: Transplantation. 1982 ; Vol. 33, No. 6. pp. 636-641.
@article{5c6d6810bb5a49768fc4a120ee1755bd,
title = "Enhanced kidney graft survival with retroplacental source γ-globulin: Results of a 5year prospective study at a single center",
abstract = "We examined the possibility that retroplacental source γ-globulin (RPGG), with its content of anti-HLA antibodies, would improve cadaver kidney graft survival rates. In a 5-year controlled prospective study of 208 transplants, we found that the addition of RPGG to a standard immunosuppressive drug regimen (azathioprine and prednisone) resulted in significant improvement of the cumulative survival rate (CSR) of first and second grafts. At 2 years, the overall CSR of first grafts increased from a control value of 37{\%} ± 6 to 52{\%} ± 6 (P = 0.037). Among second graft recipients, the CSR increased from a value of 19{\%} ± 8 to 50{\%} ± 10 (P = 0.014). This improvement in graft survival was seen as early as 3 months after surgery and was sustained through 3 years without added recipient morbidity or mortality. When recipient populations were stratified for various factors, those groupings remonstrative of an intact or active humoral immune response capacity were found to have the highest survival rates in the study; 2-year graft CSRs of 70{\%} ± 6 and 65{\%} ± 10 were found in recipients with preformed antibody resulting from blood transfusions (P = 0.003) and cytomegalovirus infectivity (P = 0.0006), respectively. These findings indicate that the improved graft survival seen in this study may have resulted from a recipient’s immunological response to challenge with RPGG.",
author = "Riggio, {Robert R.} and Manikkam Suthanthiran and Cheigh, {Jhoong S.} and Haschemeyer, {Rudy H.} and Fotino, {Marilena A.} and Stubenbord, {William T.} and Stenzel, {Kurt H.} and Rubin, {Albert L.}",
year = "1982",
month = "1",
day = "1",
doi = "10.1097/00007890-198206000-00014",
language = "English",
volume = "33",
pages = "636--641",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Enhanced kidney graft survival with retroplacental source γ-globulin

T2 - Results of a 5year prospective study at a single center

AU - Riggio, Robert R.

AU - Suthanthiran, Manikkam

AU - Cheigh, Jhoong S.

AU - Haschemeyer, Rudy H.

AU - Fotino, Marilena A.

AU - Stubenbord, William T.

AU - Stenzel, Kurt H.

AU - Rubin, Albert L.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - We examined the possibility that retroplacental source γ-globulin (RPGG), with its content of anti-HLA antibodies, would improve cadaver kidney graft survival rates. In a 5-year controlled prospective study of 208 transplants, we found that the addition of RPGG to a standard immunosuppressive drug regimen (azathioprine and prednisone) resulted in significant improvement of the cumulative survival rate (CSR) of first and second grafts. At 2 years, the overall CSR of first grafts increased from a control value of 37% ± 6 to 52% ± 6 (P = 0.037). Among second graft recipients, the CSR increased from a value of 19% ± 8 to 50% ± 10 (P = 0.014). This improvement in graft survival was seen as early as 3 months after surgery and was sustained through 3 years without added recipient morbidity or mortality. When recipient populations were stratified for various factors, those groupings remonstrative of an intact or active humoral immune response capacity were found to have the highest survival rates in the study; 2-year graft CSRs of 70% ± 6 and 65% ± 10 were found in recipients with preformed antibody resulting from blood transfusions (P = 0.003) and cytomegalovirus infectivity (P = 0.0006), respectively. These findings indicate that the improved graft survival seen in this study may have resulted from a recipient’s immunological response to challenge with RPGG.

AB - We examined the possibility that retroplacental source γ-globulin (RPGG), with its content of anti-HLA antibodies, would improve cadaver kidney graft survival rates. In a 5-year controlled prospective study of 208 transplants, we found that the addition of RPGG to a standard immunosuppressive drug regimen (azathioprine and prednisone) resulted in significant improvement of the cumulative survival rate (CSR) of first and second grafts. At 2 years, the overall CSR of first grafts increased from a control value of 37% ± 6 to 52% ± 6 (P = 0.037). Among second graft recipients, the CSR increased from a value of 19% ± 8 to 50% ± 10 (P = 0.014). This improvement in graft survival was seen as early as 3 months after surgery and was sustained through 3 years without added recipient morbidity or mortality. When recipient populations were stratified for various factors, those groupings remonstrative of an intact or active humoral immune response capacity were found to have the highest survival rates in the study; 2-year graft CSRs of 70% ± 6 and 65% ± 10 were found in recipients with preformed antibody resulting from blood transfusions (P = 0.003) and cytomegalovirus infectivity (P = 0.0006), respectively. These findings indicate that the improved graft survival seen in this study may have resulted from a recipient’s immunological response to challenge with RPGG.

UR - http://www.scopus.com/inward/record.url?scp=0019948101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019948101&partnerID=8YFLogxK

U2 - 10.1097/00007890-198206000-00014

DO - 10.1097/00007890-198206000-00014

M3 - Article

C2 - 6179273

AN - SCOPUS:0019948101

VL - 33

SP - 636

EP - 641

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 6

ER -